Secondary cost-effectiveness analysis of CASTLE-HTx (194 patients with end-stage HF and AF referred for transplant): ablation plus GDMT vs medical therapy gained ~1.7 life-years at ~€12,000, ~€8600 per QALY over a lifetime (€30,400 at 36 months).
Secondary analysisn = 194
Boettger et al. Cost-effectiveness of catheter ablation in end-stage heart failure with atrial fibrillation: Insights from CASTLE-HTx